enGene Therapeutics (ENGN) Insider Brunk Buys 31,000 Shares

Gerald Brunk recently added 31,000 shares of enGene Therapeutics Inc. (ENGN) to his holdings. The transaction took place on June 16, 2026, according to records filed with the SEC. This acquisition was part of a much larger wave of buying by the company's leadership team on the same day, signaling a collective increase in their personal stakes in the biotechnology firm.

A Coordinated Day for enGene Insiders

The purchase by Gerald Brunk was just one piece of a busy day for the company's internal roster. On June 16, 2026, several other individuals also picked up shares. Michael Thomas Heffernan, Philip Astley-Sparke, Paul Hastings, Lota Zoth, and Wouter Joustra each acquired 31,000 shares. The largest single purchase came from William Grossman, the Interim Chief Medical Officer, who acquired 231,000 shares. None of these transactions were conducted under a Rule 10b5-1 plan, which is a tool insiders often use to schedule trades in advance to avoid conflicts of interest.

enGene Therapeutics Stock Performance

Shares of enGene Therapeutics were trading at $1.74 on Wednesday. The stock has been navigating a difficult year, currently sitting much closer to its 52-week low of $1.40 than its high of $12.25. The stock is also trading under its 200-day moving average— a technical line that tracks the average price over the last 200 days — which is currently $5.36. Despite the recent price pressure, the company maintains a current ratio of 10.21, a measure of its ability to cover short-term obligations with its current assets, which suggests it has a healthy cushion of liquidity.

Recent Earnings and Financial Results

In its most recent financial reporting, enGene Therapeutics showed the typical profile of a clinical-stage biotech. The company reported a net margin of 0.0% and a return on equity of -0.60. Because the company is not yet generating a profit, it does not have a meaningful P/E ratio, which is the price of the stock divided by its earnings. The company's next earnings report is expected on January 4, 2027. Investors often watch these dates closely for updates on clinical trial progress and cash burn rates.

Analysts Set New Price Targets

Financial analysts have recently weighed in on the company's prospects. On September 9, 2026, Citizens reiterated a Market Perform rating on the stock. Just one day earlier, on September 8, 2026, HC Wainwright & Co. reiterated a Buy rating and set a $4.00 price target. Across seven different analyst opinions, the company holds a consensus recommendation of "hold" with a mean price target of $3.29. This target is nearly double the current trading price.

Genetic Medicine for Bladder Cancer

enGene Therapeutics is a Montreal-based company focused on creating genetic medicines. Their main work involves developing treatments for patients with non-muscle invasive bladder cancer. Their lead product, detalimogene voraplasmid, is currently being tested as a monotherapy. This type of biotech work often requires years of clinical trials before a product can reach the market, which explains why insiders might be looking at the long-term potential of the science rather than short-term stock fluctuations.

What to Watch at enGene Therapeutics Inc.

Investors should keep an eye on upcoming clinical data from the company's Phase 2 LEGEND trial, as trial results are often the biggest catalyst for biotech stocks. While these insider purchases show that leadership is putting their own capital into the stock, it is important to remember that these filings represent specific dates in June and may not reflect their current views or future trading plans. Further SEC filings will be the best way to see if this buying trend continues through the end of the year.